FMP
Aug 21, 2025 8:00 PM - Andrew Wynn(Last modified: Aug 22, 2025 1:33 PM)
Image credit: Google Images
Sportradar Group AG (NASDAQ:SRAD) is a leading global provider of sports data and content. The company offers a range of services, including data analytics, sports entertainment, and betting services. It competes with other companies in the sports data and technology sector, such as Genius Sports Limited and Thoughtworks Holding, Inc.
Sportradar's Return on Invested Capital (ROIC) is 6.08%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 14.17%. This indicates that the company is not currently generating returns that exceed its cost of capital. The ROIC to WACC ratio of 0.43 further highlights this inefficiency in capital utilization.
In comparison, Genius Sports Limited has a negative ROIC of -13.85% and a WACC of 12.60%, resulting in a ROIC to WACC ratio of -1.10. This suggests that Genius Sports is also struggling to generate returns above its cost of capital. Similarly, Thoughtworks Holding, Inc. has a ROIC of -3.79% and a WACC of 9.10%, leading to a ROIC to WACC ratio of -0.42.
Clearwater Analytics Holdings, Inc. and PowerSchool Holdings, Inc. also show inefficiencies in capital utilization, with ROIC to WACC ratios of -0.04 and 0.08, respectively. However, Mister Car Wash, Inc. stands out with a ROIC of 4.67% and a WACC of 6.90%, resulting in the highest ROIC to WACC ratio of 0.68 among the peers.
Aug 21, 2025 4:00 PM - Alex Lavoie
Protalix BioTherapeutics, Inc. (AMEX:PLX) is a biopharmaceutical company that focuses on the development and commercialization of recombinant therapeutic proteins. These proteins are produced using its proprietary ProCellEx plant cell-based protein expression system. The company operates in a compet...
Aug 21, 2025 4:00 PM - Alex Lavoie
Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company that focuses on developing and commercializing biosimilar drugs. These are drugs that are highly similar to already approved biological medicines, offering more affordable treatment options. Coherus competes with other biopharmac...